|Print Page | Close Window|
|February 14, 2017 - 7:01 p.m.|
Gilead Announces 144-Week Data Evaluating Safety and Efficacy of Genvoya® for Treatment of HIV-1 in Treatment-Naïve Adults
|February 13, 2017 - 6:47 p.m.|
Gilead Announces Findings from New Preclinical Study Evaluating Novel Class of HIV Capsid Inhibitors
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.